For Member Support: membersupport [at] argyleforum.com
For Client Support: clientsupport [at] argyleforum.com
(646) 839–0012
Go to Client Solutions Site
Meeting Overview

Perspectives By:

Mark Altmeyer
President and Chief Executive Officer
Otsuka America Pharmaceutical, Inc.

Linda Bowers
VP Life Sciences Product Marketing
IntraLinks

Sean Brynjelsen
Vice President, Business Development and R&D
Akorn, Inc.

Carol Cruickshank
Vice President and Partner
A.T. Kearney

Matt Cushing
Partner
Bingham McCutchen

David H. Donabedian, PhD, MBA
Vice President, Global New Deal Strategy & Development
US CEEDD, GSK

Dimitri Drone
Partner
PwC

Chris Garabedian
President & CEO, AVI BioPharma and
Former Vice President, Corporate Strategy, Celgene

Adam Golden
Partner
Kaye Scholer

Keith M. Gottesdiener, M.D.
Vice President, Development
Merck & Co., Inc.

Milton Grannatt
Vice President & Head, Negotiations, Respiratory & New Growth Opportunities Global Business Development & Licensing
Novartis Pharmaceuticals Corporation

William Hoffman
Partner
Kaye Scholer LLP

Sharon Kochan
Executive Vice President, U.S. Generics
Perrigo Company

Jeff Levy
Director, Business Development
RR Donnelley

Michael Mentesana
US Pharmaceutical and Life Sciences R&D Advisory Services Leader
PwC

Polly Murphy
VP, R&D Business Development
Pfizer Inc.

Adelene Q. Perkins
President and Chief Executive Officer
Infinity Pharmaceuticals, Inc.

Marla S. Persky
Senior Vice President, General Counsel and Secretary
Boehringer Ingelheim USA Corporation

Barry Ticho, M.D., Ph.D.
Vice President, R&D
Biogen Idec

Pol Vandenbroucke
Vice President, Clinical Development, Emerging Markets Business Unit
Pfizer

Greg Wiederrecht, PhD, CLP
Vice President & Head, External Scientific Affairs Worldwide Licensing & External Research
Merck & Co., Inc.

Michael Wise
Partner
A.T. Kearney

Brett Zbar
Partner
Aisling Capital


Summary:

As the pharmaceutical and biotech industries face pending healthcare and biologics legislation, the future of the industry remains in flux. Many companies have generics coming off patent necessitating discussion on new investments, pipeline issues and increased research & development.

These are amongst the topics that will be addressed on June 16th, when Argyle Executive Forum will host its Leadership in Pharmaceuticals and Biotechnology meeting, taking place in Manhattan.

Argyle meetings are by invitation only. If you did not receive an invitation but would like to inquire about attendance, please click here.

*Press policies for member meetings are set at the individual session level. Some sessions may be on the record, while others are off. Please consult the meeting agenda, which will indicate which sessions are off the record. To inquire about media presence, please click here.

Date: Thursday, June 16, 2011

Time: 8:00am – 5:00pm

Location: New York, NY
*Event location will be disclosed to attendees upon completion of the registration process.

Advance registration is required for all member meetings. Registration is not available onsite.

To download the program from this member meeting please fill out the form below:

First Name


Last Name


Title


Company


Email


Phone number


back to top ↑